Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Explore the role and challenges of AAV characterization, the significance of capsid filling, and the best methods to enhance ...

The IVB-2 subtype demonstrated elevated infectiousness and transgene delivery towards cerebral organoids. Figure 3. Cerebral organoids as models for (A) Parkinson’s disease and (B) AAV capsid ...

CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...

and other AAV serotypes to identify novel capsids optimized for AAV delivery for specific therapeutic applications. Voyager’s next-generation capsids are designed to deliver innovative AAV-based ...

Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange ...

Paris, France, October 22, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company developing novel delivery vectors ... of peptide conjugated AAV (coAAV) vectors that precisely ...